Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study.

BACKGROUND We investigated the incidence and outcome of progressive multifocal leukoencephalopathy (PML) in human immunodeficiency virus (HIV)-infected individuals before and after the introduction of combination antiretroviral therapy (cART) in 1996. METHODS From 1988 through 2007, 226 cases of PML were reported to the Swiss HIV Cohort Study. By chart review, we confirmed 186 cases and recorded all-cause and PML-attributable mortality. For the survival analysis, 25 patients with postmortem diagnosis and 2 without CD4+ T cell counts were excluded, leaving a total of 159 patients (89 before 1996 and 70 during 1996-2007). RESULTS The incidence rate of PML decreased from 0.24 cases per 100 patient-years (PY; 95% confidence interval [CI], 0.20-0.29 cases per 100 PY) before 1996 to 0.06 cases per 100 PY (95% CI, 0.04-0.10 cases per 100 PY) from 1996 onward. Patients who received a diagnosis before 1996 had a higher frequency of prior acquired immunodeficiency syndrome-defining conditions (P = .007) but similar CD4+ T cell counts (60 vs. 71 cells/microL; P = .25), compared with patients who received a diagnosis during 1996 or thereafter. The median time to PML-attributable death was 71 days (interquartile range, 44-140 days), compared with 90 days (interquartile range, 54-313 days) for all-cause mortality. The PML-attributable 1-year mortality rate decreased from 82.3 cases per 100 PY (95% CI, 58.8-115.1 cases per 100 PY) during the pre-cART era to 37.6 cases per 100 PY (95% CI, 23.4.-60.5 cases per 100 PY) during the cART era. In multivariate models, cART was the only factor associated with lower PML-attributable mortality (hazard ratio, 0.18; 95% CI, 0.07-0.50; P < .001), whereas all-cause mortality was associated with baseline CD4+ T cell count (hazard ratio per increase of 100 cells/microL, 0.52; 95% CI, 0.32-0.85; P = .010) and cART use (hazard ratio, 0.37; 95% CI, 0.19-0.75; P = .006). CONCLUSIONS cART reduced the incidence and PML-attributable 1-year mortality, regardless of baseline CD4+ T cell count, whereas overall mortality was dependent on cART use and baseline CD4+ T cell count.

[1]  B. Brew.  Faculty Opinions recommendation of PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. , 2009 .

[2]  K. Tobinai,et al.  Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature , 2008, International journal of hematology.

[3]  C. Marra,et al.  Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis , 2008, AIDS.

[4]  D. Podzamczer,et al.  Influence of HAART on the Clinical Course of HIV-1-Infected Patients With Progressive Multifocal Leukoencephalopathy: Results of an Observational Multicenter Study , 2008, Journal of acquired immune deficiency syndromes.

[5]  P. Quesenberry,et al.  Newer monoclonal antibodies for hematological malignancies. , 2008, Experimental hematology.

[6]  D. Focosi,et al.  Progressive multifocal leukoencephalopathy: report of three cases in HIV-negative hematological patients and review of literature , 2008, Annals of Hematology.

[7]  K. Khalili,et al.  Cross-Interaction between JC Virus Agnoprotein and Human Immunodeficiency Virus Type 1 (HIV-1) Tat Modulates Transcription of the HIV-1 Long Terminal Repeat in Glial Cells , 2006, Journal of Virology.

[8]  J. Berger,et al.  Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab , 2006, Neurological research.

[9]  F. Barkhof,et al.  Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. , 2006, The New England journal of medicine.

[10]  I. Krsnik,et al.  Changes in the natural history of progressive multifocal leukoencephalopathy in HIV‐negative lymphoproliferative disorders: Impact of novel therapies , 2005, American journal of hematology.

[11]  A. Giordano,et al.  Investigation on the role of cell transcriptional factor Sp1 and HIV‐1 TAT protein in PML onset or development , 2005, Journal of cellular physiology.

[12]  A. De Luca,et al.  Reduced Rate of Diagnostic Positive Detection of JC Virus DNA in Cerebrospinal Fluid in Cases of Suspected Progressive Multifocal Leukoencephalopathy in the Era of Potent Antiretroviral Therapy , 2005, Journal of Clinical Microbiology.

[13]  K. Tyler,et al.  Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. , 2005, The New England journal of medicine.

[14]  A. Lazzarin,et al.  Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  J. Rockstroh,et al.  Progressive Multifocal Leukencephalopathy in Patients on Highly Active Antiretroviral Therapy: Survival and Risk Factors of Death , 2004, Journal of acquired immune deficiency syndromes.

[16]  M. Battegay,et al.  Immune reconstitution in HIV-infected patients. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  J. Mallolas,et al.  Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  A. Safdar,et al.  Fatal immune restoration disease in human immunodeficiency virus type 1-infected patients with progressive multifocal leukoencephalopathy: impact of antiretroviral therapy-associated immune reconstitution. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  D. Clifford,et al.  A PILOT STUDY OF CIDOFOVIR FOR PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY IN AIDS , 2002, AIDS.

[20]  J. Schmitz,et al.  Association of Prolonged Survival in HLA-A2+ Progressive Multifocal Leukoencephalopathy Patients with a CTL Response Specific for a Commonly Recognized JC Virus Epitope1 , 2002, The Journal of Immunology.

[21]  L. Larocca,et al.  AIDS-related focal brain lesions in the era of highly active antiretroviral therapy , 2000, Neurology.

[22]  M Egger,et al.  AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. , 1999, JAMA.

[23]  R. Chaisson,et al.  Natural history of HIV infection in the era of combination antiretroviral therapy. , 1999, AIDS.

[24]  D. Costagliola,et al.  Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors. Clinical Epidemiology Group. French Hospital Database on HIV. , 1999, AIDS.

[25]  A. Antinori,et al.  Clinical and virological monitoring during treatment with intrathecal cytarabine in patients with AIDS-associated progressive multifocal leukoencephalopathy. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  D M Simpson,et al.  HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy , 1999, Neurology.

[27]  M. Battegay,et al.  HIV-1-infected patients with focal neurologic signs: diagnostic role of PCR for Toxoplasma gondii, Epstein-Barr virus, and JC virus. , 1998, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[28]  R. Levy,et al.  Predictive factors for prolonged survival in acquired immunodeficiency syndrome—associated progressive multifocal leukoencephalopathy , 1998, Annals of neurology.

[29]  H. Stellbrink,et al.  Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV‐associated progressive multifocal leukoencephalopathy , 1998, AIDS.

[30]  U. Dafni,et al.  Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. , 1998, The New England journal of medicine.

[31]  J. Cervós-Navarro,et al.  The neuropathology and epidemiology of AIDS. A Berlin experience. A review of 200 cases. , 1995, Pathology, research and practice.

[32]  R. Levy,et al.  Progressive multifocal leukoencephalopathy in patients with HIV infection: lack of impact of early diagnosis by stereotactic brain biopsy. , 1992, Journal of acquired immune deficiency syndromes.

[33]  G. Rutherford,et al.  Progressive multifocal leukoencephalopathy in persons infected with human immunodeficiency virus, san francisco, 1981–1989 , 1991, Annals of neurology.

[34]  M. Post,et al.  Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases. , 1987, Annals of internal medicine.

[35]  B. Padgett,et al.  Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. , 1971, Lancet.

[36]  G. Z. Zu Rhein,et al.  Particles Resembling Papova Viruses in Human Cerebral Demyelinating Disease , 1965, Science.

[37]  E. Richardson.  Progressive multifocal leukoencephalopathy. , 1961, The New England journal of medicine.

[38]  D. Clifford,et al.  The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: Defining a consensus terminology , 2011, Journal of NeuroVirology.

[39]  A. Rojiani,et al.  Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature , 2007, Bone Marrow Transplantation.

[40]  The Swiss Hiv Cohort Study,et al.  The Swiss HIV Cohort Study: Rationale, organization and selected baseline characteristics , 2005, Sozial- und Präventivmedizin.

[41]  A. Lazzarin,et al.  Diagnosis of central nervous system complications in HIV-infected patients: cerebrospinal fluid analysis by the polymerase chain reaction. , 1997, AIDS.

[42]  E. Major,et al.  Progressive multifocal leukoencephalopathy: molecular biology, pathogenesis and clinical impact. , 1997, Intervirology.